Vor Biopharma Inc. VOR
We take great care to ensure that the data presented and summarized in this overview for Vor Biopharma Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VOR
View all-
Ra Capital Management, L.P. Boston, MA39.6MShares$54.3 Million0.71% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA6.36MShares$8.72 Million3.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.94MShares$2.66 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ1.07MShares$1.47 Million0.41% of portfolio
-
Lynx1 Capital Management LP San Juan, PR637KShares$872,9880.27% of portfolio
-
Sarissa Capital Management LP Greenwich, CT618KShares$846,6600.21% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny530KShares$725,4150.0% of portfolio
-
Black Rock Inc. New York, NY498KShares$681,8430.0% of portfolio
-
Geode Capital Management, LLC Boston, MA422KShares$578,3350.0% of portfolio
-
Oup Management Co., LLC375KShares$513,3581.79% of portfolio
Latest Institutional Activity in VOR
Top Purchases
Top Sells
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at VOR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 13
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,227
-1.73%
|
$2,227
$1.42 P/Share
|
|
Feb 10
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,554
-1.94%
|
$2,554
$1.37 P/Share
|
|
Feb 06
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,180
-0.89%
|
$1,180
$1.5 P/Share
|
|
Feb 06
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,787
-0.3%
|
$2,787
$1.5 P/Share
|
|
Feb 06
2025
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,033
-0.47%
|
$1,033
$1.5 P/Share
|
|
Feb 03
2025
|
Han Wook Choi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+50.0%
|
-
|
|
Feb 03
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+28.37%
|
-
|
|
Feb 03
2025
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,353
-1.66%
|
$1,353
$1.34 P/Share
|
|
Feb 03
2025
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+19.18%
|
-
|
|
Feb 03
2025
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,163
-0.68%
|
$1,163
$1.34 P/Share
|
|
Feb 03
2025
|
Robert Ang PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
137,500
+12.98%
|
-
|
|
Feb 03
2025
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,248
-0.41%
|
$3,248
$1.34 P/Share
|
|
Dec 30
2024
|
Reprogrammed Interchange LLC |
BUY
Open market or private purchase
|
Direct |
38,974,101
+50.0%
|
-
|
|
Dec 30
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
16,897,159
+30.88%
|
-
|
|
Dec 27
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,334
-11.26%
|
$10,334
$1.25 P/Share
|
|
Nov 06
2024
|
Tirtha Chakraborty CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
875
-0.51%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,361
-0.3%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Eyal C. Attar CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
999
-1.08%
|
$0
$0.86 P/Share
|
|
Nov 06
2024
|
Amy Quinlan Vice President of Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
206
-0.41%
|
$0
$0.86 P/Share
|
|
Nov 01
2024
|
Robert Ang PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,751
-0.35%
|
$0
$0.8 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 17.2M shares |
|---|---|
| Open market or private purchase | 39M shares |
| Payment of exercise price or tax liability | 88.1K shares |
|---|---|
| Open market or private sale | 29.8K shares |